Julian Schmidt

Julian Schmidt

Auto-generated profile, based on publicly available information

Julian Schmidt

Johannes Gutenberg University, Mainz

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2025 in Journal of the American Chemical Society
Verified
Journal Article
Open access
PDPhilip Dreier
Philip Dreier
RMRebecca Matthes
Rebecca Matthes
FFFabian Fuß
Fabian Fuß
JSJulian Schmidt
Julian Schmidt
DSDominik Schulz
Dominik Schulz
HFHolger Frey
Holger Frey
PEGylation, the conjugation of poly(ethylene glycol) (PEG) to nanocarriers or protein-based active pharmaceutical ingredients (APIs), is a key strategy in nanomedicine to extend the circulation time of therapeutics in the bloodstream based on the stealth effect of PEG. However, the growing prevalence of anti-PEG antibodies in the population can lead to pronounced immune responses upon drug administration and accelerated blood clearance of PEGylated drugs, resulting in the loss of the stealth effect. We introduce the randomized PEG (rPEG) technology designed to strongly reduce the antigenicity of PEG while preserving its core benefits. This conceptually novel approach is based on an introduction of hydrophilic side chains along the PEG backbone. The synthesis is performed via anionic ring-opening copolymerization of ethylene oxide (EO) and glycidyl methyl ether (GME), resulting in constitutional isomers of PEG. By optimization of the reaction conditions, an ideally random distribution of the side chains in the polymer backbone could be achieved. Since previous studies show a relation between polymer chain regularity and immune system response, our approach specifically aims at introducing an irregular comonomer sequence via copolymerization, while translating the hydrophilicity and low toxicity of PEG to rPEG. Biocompatibility was evaluated using peripheral blood mononuclear cells (PBMC). Increasing the GME content in the copolymers did not decrease cell viability. Furthermore, all rPEG samples did not show complement activation in vitro at all tested concentrations. Enzyme-linked immunosorbent assays (ELISA) utilizing backbone- and end group-selective anti-PEG antibodies showed drastically reduced recognition and antibody binding for the constitutional isomers of PEG.

24 December 2025 in Macromolecular Rapid Communications
Verified
Journal Article
Open access
JSJulian Schmidt
Julian Schmidt
AZAnna‐Lena Ziegler
Anna‐Lena Ziegler
FKFlorian T. Kaps
Florian T. Kaps
LRLaura J. Rosenberger
Laura J. Rosenberger
MBMatthias Bros
Matthias Bros
RLRobert Luxenhofer
Robert Luxenhofer
Polyethylene glycol (PEG) plays a central role in nanomedicine, providing essential properties such as the stealth effect. However, the emergence of anti‐PEG antibodies (APAs) increasingly undermines these benefits, raising concerns about safety and efficiency. This creates an urgent need for PEG alternatives. Randomized PEG (rPEG) represents a conceptually new strategy that preserves the PEG‐like structure and performance while markedly reducing antigenicity. In this work, rPEG is employed as a non‐antigenic A‐block in ABA‐type polymeric micelles (PMs). To enhance drug loading capacity beyond conventional PMs, the hydrophobic middle block is composed of poly(2‐phenyl‐2‐oxazine) (PPheOzi). rPEG is synthesized by anionic ring‐opening polymerization, PPheOzi by cationic ring‐opening polymerization, and the combined rPEG‐ b ‐PPheOzi‐ b ‐rPEG triblock copolymers are linked via copper‐catalyzed azide‐alkyne cycloaddition. The formulations exhibit a distinct correlation between the solubilization of Efavirenz and the systematically varied rPEG composition, ranging from outstanding to moderate micelle drug loading capacities. A fundamental preclinical safety profile was established through investigations in murine fibroblasts and human peripheral blood mononuclear cells (PBMCs). Competitive enzyme‐linked immunosorbent assays (ELISA) revealed a pronounced reduction in APA affinity in comparison to PEG. Taken together, the synergistic combination of rPEG and PPheOzi establishes a non‐antigenic micellar platform capable of achieving high drug loadings.

29 May 2026 in Chemical Science
Verified
Journal Article
Open access
PDF file
PDPhilip Dreier
Philip Dreier
CBCaroline Bockhard
Caroline Bockhard
DSDavid Seibel
David Seibel
OSOlaf Soltwedel
Olaf Soltwedel
RMRebecca Matthes
Rebecca Matthes
HFHolger Frey
Holger Frey
PEG lipids are essential excipients in lipid nanoparticle (LNP) formulations and enable the transport of therapeutic ribonucleic acids, creating stealth properties for these nanocarriers. However, an increasing number of studies raise concerns related to the growing presence of anti-PEG antibodies (APA) in the population. The presence of APAs results in the recognition and accelerated blood clearance of PEGylated therapeutics, thus diminishing the desired stealth effect of PEGylation. In this study, we present the isomerization of PEG to randomized PEG (rPEG) as an efficient approach for inhibiting APA interaction while preserving the advantages of PEG. rPEGs were obtained via living anionic ring-opening (co)polymerization (AROP) of ethylene oxide (EO) with glycidyl methyl ether (GME). This yields rPEGs with narrow molar mass distributions (Mw/Mn = 1.04–1.10) for all EO:GME compositions synthesized. Chain-end functionalization of rPEGs with lipid anchor groups was conducted to obtain rPEG lipids with C14-chains (ditetradecylacetamide (DTAA), dimyristoyl-glycerol (DMG)). APA interaction was investigated via enzyme-linked immunosorbent assay (ELISA) and X-ray reflectometry (XRR) at monolayers of the rPEG lipid, allowing for a general understanding of the relation between the chain architecture and APA interaction. LNPs containing rPEG lipids were formulated and compared to established PEG-based LNPs, showing similar particle sizes, encapsulation and transfection efficiencies, and cell viabilities for a variety of cell lines. It is demonstrated that rPEG lipids can prevent APA binding but nevertheless exhibit similar performance in LNPs as comparable PEG lipids.

7 August 2026 in Advanced Drug Delivery Reviews
Verified
Journal Article
Open access
JSJulian Schmidt
Julian Schmidt
CBCaroline Bockhard
Caroline Bockhard
LSLea Simon
Lea Simon
GLGregor M. Linden
Gregor M. Linden
JSJohannes M. Scheiger
Johannes M. Scheiger
HFHolger Frey
Holger Frey

4 August 2026 in Biomacromolecules
Verified
Journal Article
Open access
VMVerena MülLer
Verena MülLer
JSJulian Schmidt
Julian Schmidt
RMRebecca Matthes
Rebecca Matthes
PDPhilip Dreier
Philip Dreier
SSSandra SchütTner
Sandra SchütTner
HFHolger Frey
Holger Frey
Anti-PEG antibodies (APAs) lead to accelerated blood clearance of PEGylated drugs and nanocarriers. Randomized PEG (rPEG) reduces APA recognition by randomly incorporating glycidyl methyl ether in PEG. Extending this concept, statistical copolymerization of ethylene oxide with ethyl glycidyl ether (EGE) or isopropyl glycidyl ether (iPGE) was investigated. Copolymers of EO with 13–28 mol % EGE or 6–20 mol % iPGE showed low dispersity (Đ ≤ 1.09). Via online-NMR monitoring, reactivity ratios in DMSO were rEO = 1.39 and rEGE = 0.72 for P(EO-co-EGE) and rEO = 1.35 and riPGE = 0.74 for P(EO-co-iPGE). All copolymers were soluble in PBS buffer at physiological temperatures and noncytotoxic, except for 20% iPGE content, shown by cell viability and immunostimulatory effects on murine splenocytes. All copolymers exhibit significantly reduced APA recognition (ELISA) with stronger effects for the sterically demanding iPGE. The findings highlight mP(EO-co-EGE) and mP(EO-co-iPGE) as promising PEG alternatives for nanomedicine and bioconjugation.